MedPage Today provides expert commentary on conferences and research on a full range of medical conditions. The following articles on research presented at the recent Genitourinary Cancers Symposium (13-15 Feb) are all worthy of your time. Each provides concise summary commentary and links to all sources mentioned in the articles:
1. What's the Better Option for High-Risk Prostate Cancer -- Radiation or Surgery?— Study shows higher rates of distant metastasis with surgery, but similar cancer-specific survival, Meeting Coverage > GuCS, by Mike Bassett, Staff Writer, MedPage Today, February 14, 2025.
medpagetoday.com/meetingcov...
2. Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC — Survival benefit especially large in patients with HRR gene alterations, Meeting Coverage > GuCS, by Mike Bassett, Staff Writer, MedPage Today, February 13, 2025.
medpagetoday.com/meetingcov...
3. Radiographic PFS in Metastatic CRPC More Than Doubles With Novel Combination — Improvement from 6.2 to 14.3 months with mevrometostat plus enzalutamide, but with more toxicity, Meeting Coverage > GuCS, by Mike Bassett, Senior Editor, MedPage Today, February 13, 2025.
medpagetoday.com/meetingcov...
4. Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC — Combination also improved quality of life in phase II study, Meeting Coverage > GuCS, by Mike Bassett, Staff Writer, MedPage Today, February 14, 2025.
medpagetoday.com/meetingcov...
5. Metastasis-Directed Therapy for Prostate Cancer a Clear Winner in Meta-Analysis — PFS more than doubled with standard of care plus MDT, but practice continues to evolve, Meeting Coverage > GuCS, by Mike Bassett, Senior Editor, MedPage Today, February 14, 2025.
medpagetoday.com/meetingcov...
Stay/Be S&W,
Ciao - cujoe
